Guardant Health Inc
Company Profile
Business description
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
Contact
3100 Hanover Street
Palo AltoCA94304
USAT: +1 855 698-8887
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 December 2025
Employees
2,021
Stocks News & Analysis
stocks
Going into earnings, is Netflix stock a buy, a sell, or fairly valued?
stocks
Bapcor is paying for the sins of its past
stocks
Overvalued ASX share as market underestimates downside risks
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 9,390.10 | 16.40 | 0.17% |
CAC 40 | 8,214.46 | 8.39 | 0.10% |
DAX 40 | 24,268.55 | 9.75 | 0.04% |
Dow JONES (US) | 46,706.58 | 515.97 | 1.12% |
FTSE 100 | 9,435.43 | 31.86 | 0.34% |
HKSE | 26,022.74 | 163.91 | 0.63% |
NASDAQ | 22,990.54 | 310.57 | 1.37% |
Nikkei 225 | 49,316.06 | 130.56 | 0.27% |
NZX 50 Index | 13,377.85 | 32.89 | 0.25% |
S&P 500 | 6,735.13 | 71.12 | 1.07% |
S&P/ASX 200 | 9,094.70 | 18.80 | 0.21% |
SSE Composite Index | 3,916.33 | 52.44 | 1.36% |